trending Market Intelligence /marketintelligence/en/news-insights/trending/PC1p73NzwpHc91X1-0iihg2 content esgSubNav
In This List

Genebiotech Q1 profit climbs YOY

Podcast

Street Talk | Episode 105: Banks could see opportunity in fintech's cleansing fire

Blog

The Climate Vulnerability Assessment by APRA: Helping Financial Institutions Address Challenges

Video

Lithium Import

Blog

Activity Volumes Across the Equity Capital Markets Dropped Significantly in 2022


Genebiotech Q1 profit climbs YOY

Genebiotech Co. Ltd. said its first-quarter normalized net income amounted to 36.81 South Korean won per share, a gain from 17.66 won per share in the prior-year period.

Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was 266.5 million won, a gain from 119.9 million won in the prior-year period.

The normalized profit margin increased to 2.4% from 1.0% in the year-earlier period.

Total revenue declined 5.2% year over year to 11.30 billion won from 11.92 billion won, and total operating expenses decreased 6.7% from the prior-year period to 11.31 billion won from 12.12 billion won.

Reported net income totaled 166.4 million won, or 22.99 won per share, compared to a loss of 54.7 million won, or a loss of 8.06 won per share, in the year-earlier period.

As of May 14, US$1 was equivalent to 1,090.69 South Korean won.